Verona Pharma (VRP)

 

Latest News

Verona Pharma losses deepen

Verona Pharma said its third-quarter losses more than tripled after research and development costs rose. The company boo...

Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017 Emerging clinical data confirms the potential for RPL554 to be an important, novel treatment for patients with COPD LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma" or the "Compan...

Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment

Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment Top-line data from the study now expected in mid-2018 LONDON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutic...

Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017 LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respirator...

All News

DateHeadlineSource
07-11-17Verona Pharma losses deepenStockMarketWire
07-11-17Verona Pharma plc Operational Update and Financial Results for the Third Quarter Ended September 30, 2017RNS
07-11-17Verona Pharma Reports Patient Enrollment Progressing Ahead of Schedule in Ongoing Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentRNS
31-10-17Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017RNS
31-10-17Verona Pharma to Present at Two Upcoming Investor ConferencesRNS
02-10-17Verona Pharma plc : Total voting rightsRNS
29-09-17Best AIM companies of 2017 Interactive Investor
27-09-17Verona Pharma Reports Positive Top-Line Data from U.S. Pharmacokinetic Trial Demonstrating Nebulized RPL554 Delivers Optimal Clinical Dose to PatientsRNS
19-09-17Verona to issue sharesStockMarketWire
19-09-17Verona Pharma plc : MiscellaneousRNS
07-09-17Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)RNS
01-09-17Verona Pharma Appoints Stifel as Nominated AdviserRNS
21-08-17Director Deals - Verona Pharma PLC (VRP)StockMarketWire
21-08-17PDMR DealingRNS
08-08-17Verona Pharma losses widen as it starts clinical trialsStockMarketWire
08-08-17Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development UpdateRNS
02-08-17Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development UpdateRNS
01-08-17Verona to present at healthcare conferenceStockMarketWire
01-08-17Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare ConferenceRNS
26-07-17Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance TreatmentRNS
27-06-17Verona nears Phase 2b clinical trial for RPL554StockMarketWire
27-06-17Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across EuropeRNS
22-06-17Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory AffairsRNS
06-06-17Verona Pharma plc : Holding(s) in CompanyRNS
06-06-17Verona Pharma plc : Holding(s) in CompanyRNS
05-06-17Verona initiates US clinical pharmacokinetic study for RPL554StockMarketWire
05-06-17Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDARNS
30-05-17Holding(s) in CompanyRNS
30-05-17Holding(s) in CompanyRNS
25-05-17Holding(s) in CompanyRNS
25-05-17Verona Pharma Announces Further Exercise of Over-Allotment Option and Resulting Total Voting RightsRNS
23-05-17Verona CEO to present at Jefferies Healthcare ConferenceStockMarketWire
23-05-17Verona Pharma to Present at Jefferies 2017 Global Healthcare ConferenceRNS
23-05-17Holding(s) in CompanyRNS
22-05-17Broker Forecast - Jefferies International issues a broker note on Verona Pharma PLCStockMarketWire
16-05-17Partial Exercise of Over-Allotment OptionRNS
08-05-17Holding(s) in CompanyRNS
05-05-17Holding(s) in CompanyRNS
05-05-17Holding(s) in CompanyRNS
05-05-17Holding(s) in CompanyRNS

RSS feeds

  • Editorial news feed for LSE:VRP Editorial
  • Regulatory news feed for LSE:VRP Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account